| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Nicaraven is a hydroxyl radical scavenger with antivasospastic and neuroprotective effects. Nicaraven causes a dose-dependent, slight inhibition of poly (ADP-ribose) synthetase activation, possibly due to a direct inhibitory effect on the catalytic activity of poly (ADP-ribose) synthetase in RAW murine macrophages stimulated with peroxynitrite. Nicaraven partially protects against the peroxynitrite-induced suppression of mitochondrial respiration in RAW macrophages and causes a slight, dose-dependent inhibition of nitrite production in RAW macrophages stimulated with bacterial lipopolysaccharide.
| ln Vitro |
Nicaraven, in concentration levels of 350 μM or higher, considerably inhibits the maximal aggregation rate generated by adenosine diphosphate (ADP) in the healthy volunteer platelets. 1.75 mM of nicaraven considerably reduces the maximal aggregation rate generated by collagen[1].
|
||
|---|---|---|---|
| ln Vivo |
Nicaraven suppresses liver enzyme release, endothelin-1 rise in hepatic venous blood, histologic damage, and neutrophil infiltration into the liver[1]. It also improves hepatic and systemic hemodynamics and energy metabolism. Nicaraven also inhibits lipid peroxidation in the liver. In bone marrow and peripheral blood, Nicaraven increases the quantity of c-kit(+) stem/progenitor cells, and in age-matched, non-irradiated healthy mice, the recovery rate ranges from 60 to 90%. Nicaraven treatment entirely protects the potency of colony formation from hematopoietic stem/progenitor cells as an indicator of function[2]. When hematopoietic stem/progenitor cells are administered with nicaraven, their number grows dramatically, their capacity to form colonies improves, and their DNA damage is reduced. Mice treated with nicaraven had considerably lower urinary levels of 8-oxo-2′-deoxyguanosine, a measure of DNA oxidation, than mice given a placebo. When mice are administered nicaraven, their plasma levels of TNF-α and IL-6, two inflammatory cytokines, are considerably reduced[3].
|
||
| Animal Protocol |
|
||
| References |
[1]. Komiya T, et al. A novel free radical scavenger, nicaraven, inhibits human platelet aggregation in vitro. Clin Neuropharmacol. 1999 Jan-Feb;22(1):11-4.
[2]. Yokota R, et al. A novel hydroxyl radical scavenger, nicaraven, protects the liver from warm ischemia and reperfusion injury. Surgery. 2000 Jun;127(6):661-9. [3]. Ali H, et al. The potential benefits of nicaraven to protect against radiation-induced injury in hematopoietic stem/progenitor cells with relative low dose exposures. [4]. Nicaraven attenuates radiation-induced injury in hematopoietic stem/progenitor cells in mice. PLoS One. 2013;8(3):e60023 |
| Molecular Formula |
C15H16N4O2
|
|
|---|---|---|
| Molecular Weight |
284.31
|
|
| CAS # |
79455-30-4
|
|
| Related CAS # |
|
|
| SMILES |
O=C(C1=C([H])N=C([H])C([H])=C1[H])N([H])C([H])(C([H])([H])[H])C([H])([H])N([H])C(C1=C([H])N=C([H])C([H])=C1[H])=O
|
|
| InChi Key |
KTXBOOWDLPUROC-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C15H16N4O2/c1-11(19-15(21)13-5-3-7-17-10-13)8-18-14(20)12-4-2-6-16-9-12/h2-7,9-11H,8H2,1H3,(H,18,20)(H,19,21)
|
|
| Chemical Name |
N,N-(propane-1,2-diyl)dinicotinamide
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (9.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (9.67 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.75 mg/mL (9.67 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 33.33 mg/mL (117.23 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5173 mL | 17.5864 mL | 35.1729 mL | |
| 5 mM | 0.7035 mL | 3.5173 mL | 7.0346 mL | |
| 10 mM | 0.3517 mL | 1.7586 mL | 3.5173 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA